Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001178913-18-000468 0001321178 XXXXXXXX LIVE 5 Ordinary Shares, par value NIS 0.1 per share 04/28/2025 false 0001684693 M8694L103 Sol-Gel Technologies Ltd 6 HaChoshlim St., Bldg. C Herzliya L3 6701101 Perry Wildes, Adv. 972-3-607-4444 One Azrieli Center Tel Aviv L3 6701101 0001321178 Moshe Arkin b PF L3 381343 18068564 381343 18068564 18449907 N 61.79 IN Rows (7) (8) (9) (10) and (11): The beneficial ownership of the securities reported herein is described in Items 5(a) and (b). Row (13): Based on 27,857,620 Ordinary Shares outstanding on April 15, 2025 reported by Sol-Gel in its Annual Report on Form 20-F filed on April 29, 2025. Y M. Arkin Dermatology Ltd. b WC L3 0 18068564 0 18068564 18068564 N 60.52 CO Rows (8) (10) and (11): The beneficial ownership of the securities reported herein is described in Items 5(a) and (b). Row (13): Based on 27,857,620 Ordinary Shares outstanding on April 15, 2025 reported by Sol-Gel in its Annual Report on Form 20-F filed on April 29, 2025. Ordinary Shares, par value NIS 0.1 per share Sol-Gel Technologies Ltd 6 HaChoshlim St., Bldg. C Herzliya L3 6701101 Moshe Arkin purchased Ordinary Shares on the following dates and at the following prices per share: on August 21, 2024, Mr. Arkin purchased 33,388 Ordinary Shares at a price of $0.55 per share; on August 23, 2024, Mr. Arkin purchased 30,000 Ordinary Shares at an average price of $0.70 per share; on August 26, 2024, Mr. Arkin purchased 30,000 Ordinary Shares at an average price of $0.61 per share; on August 27, 2024, Mr. Arkin purchased 46,845 Ordinary Shares at a price of $0.60 per share; on September 9, 2024, Mr. Arkin purchased 18,995 Ordinary Shares at a price of $0.58 per share; on April 23, 2025, Mr. Arkin purchased 59,437 Ordinary Shares at a price of $0.66 per share; on April 24, 2025, Mr. Arkin purchased 50,210 Ordinary Shares at a price of $0.76 per share; on April 25, 2025, Mr. Arkin purchased 22,823 Ordinary Shares at an average price of $0.76 per share; and on April 28, 2025, Mr. Arkin purchased 3,645 Ordinary Shares at an average price of $0.80 per share. Item 5 of Schedule 13D is hereby amended and restated as follows: (a) and (b) As of April 28, 2025, Arkin Dermatology owned directly (and therefore is deemed the beneficial owner of) 18,068,564 Ordinary Shares, which represented beneficial ownership of approximately 60.52% of the Company's outstanding Ordinary Shares. Arkin Dermatology has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Dermatology. As of April 28, 2025, Mr. Arkin owned directly (and therefore is deemed the beneficial owner of) 381,343 Ordinary Shares, which represented beneficial ownership of approximately 1.37% of the Company's outstanding Ordinary Shares. Mr. Arkin has the sole power to vote, or direct the voting of, and the sole power to dispose of, or direct the disposition of, these Ordinary Shares. In addition, as the sole shareholder and sole director of Arkin Dermatology, Mr. Arkin may be deemed to be the indirect beneficial owner of the 18,068,564 Ordinary Shares beneficially owned by Arkin Dermatology, which represented beneficial ownership of approximately 60.52% of the Company's outstanding Ordinary Shares. Mr. Arkin has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Dermatology. The total Ordinary Shares beneficially owned by Mr. Arkin as of April 28, 2025, is 18,449,907, which represented beneficial ownership of 61.79% of the Company's outstanding Ordinary Shares. Except as set forth in this Schedule 13D, to the best knowledge of the Reporting Persons, none of the Reporting Persons has beneficial ownership of, or has engaged in any transaction during the past 60 days in respect of, any Ordinary Shares. No person, other than the Reporting Persons, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares referred to in this Item 5. Percentages set forth in this amended Schedule 13D were calculated based on 27,857,620 Ordinary Shares outstanding on April 15, 2025. Figures were provided by the Issuer. Moshe Arkin /s/ Moshe Arkin Moshe Arkin 04/30/2025 M. Arkin Dermatology Ltd. /s/ Moshe Arkin Moshe Arkin, Director 04/30/2025